Introduction {#S1}
============

Mesenchymal stem cells (MSCs) are capable of differentiating into a limited yet diverse range of cells, and secrete regenerative factors that contribute to the repair of damaged tissues ([@B76]). MSCs in humans and animals have numerous characteristics, including the expression of specific cell surface markers, some of which are used as criteria for the detection of MSCs in tissues. The International Society for Cellular Therapy proposed that human MSCs should be identified according to positive expression for CD73, CD90, and CD105, and negative for CD11b or CD14, CD19 or CD79α, CD34, CD45, and HLA-DR expression ([@B9]). MSCs have been identified in several tissues, including the bone marrow, adipose tissue, cord blood, placenta, and pulp ([@B59]). MSCs have also been reported to migrate to wound sites during the healing process ([@B88]). Specifically, MSCs have been shown to move from the perivascular area of tissue into the blood circulation in response to signals emitted after tissue damage, and subsequently MSCs in the blood circulation may accumulate in damaged tissue ([@B66]; [@B22]). Thus, MSCs exhibit homing properties, which allows for their spontaneous accumulation at the site of injury.

It has been shown that methods capable of promoting the migration and homing of MSCs to damaged tissue enhance their effect in cell therapy ([@B57]). These models have been reported to implement several approaches including the preconditioning of MSCs, recombinant MSCs, engineering of cell surface proteins of MSCs, and modification of target tissues ([@B1]). To assess MSC migration *in vitro*, either the Boyden chamber method or the Transwell method have been used, which examine movement between concentration gradients, created by separating active substances with a permeable membrane, or by the Scratch wound method using movement in two dimensions, respectively ([@B25]). Alternatively, for the detection of MSC migration *in vivo*, researchers have developed MSCs labeled with fluorescent dyes, magnetic substances, and radioactive substances, or genetically modified MSCs that express reporters, which are transplanted into a living organism ([@B33]). Recently, several clinical trials using cell therapy to transfer exogenous MSCs into the body for treatment of various types of tissue damage and diseases, have demonstrated many advantages and are nearing completion \[clinical trials databases: [www.clinicaltrials.gov](http://www.clinicaltrials.gov), 306 studies using MSCs with study completed status in February 2020\]. The application of MSC therapy has been reported for a broad range of disorders, including various skin diseases, bone defects, cardiac disorders, and brain damage ([@B30]; [@B80]; [@B87]; [@B60]). In addition, advanced research has been conducted to develop MSCs as cell vectors for application in cancer treatment ([@B55]). Therefore, new materials that enhance the recruitment of transplanted MSCs into damaged tissues, may further improve their therapeutic effect.

Cell migration is stimulated by chemokines, cytokines, growth factors, and other biomolecules, through a number of molecularly and pharmacologically defined signaling pathways ([@B52]). MSC migration has been shown to be activated by factors such as CXCL12 (SDF-1), MIP-1, HGF, VEGF, and PDGF. Moreover, specific signaling pathway molecules including CXCR4, phosphatidylinositol 3-kinase (PI3K), mitogen-activated protein kinase (MAPK), and small G proteins have been reported to be involved in the regulation of MSC migration. It has also been reported that hypoxic preconditioning stimulates the expression of genes involved in cell migration, thereby activating MSC migration ([@B66]; [@B53]). Upon reaching the target site, MSCs can degrade the intercellular matrix and use as a scaffold to migrate through tissue.

Medicinal plants have historically been used in folk medicine to relieve various symptoms and diseases. Studies of compounds derived from medicinal plants have shown that they can molecularly activate various functions in cells and tissues ([@B71]). In fact, it has been reported that plant-derived components can activate signal transduction pathways related to cell motility ([@B7]). Although there are few reports concerning plant-related components involved in MSC migration, they represent a promising class of potential candidates to enhance the therapeutic effects of MSC therapy. Nevertheless, it has been reported that plant-derived components activate MSC migration through specific signaling pathways, mobilize MSCs to injured organs, and have healing effects. Moreover, such information may be useful for identifying more effective chemical compounds in the future. Therefore, this article reviews plant-derived components that have been shown to activate MSC migration, and homing, to damaged sites in animal models, where they contribute to the healing process.

Activation of MSC Migration by Plant-Derived Components {#S2}
=======================================================

Several studies have reported that plant-derived components promote MSC migration, which may contribute to healing of damaged tissue ([Table 1](#T1){ref-type="table"}). This effect is triggered by stimulating mechanisms involved in MSC migration ([Figure 1](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). Below we discuss the implicated plant-derived components in detail.

###### 

Plant-derived components promote MSC migration and healing in animal models.

  **Component**                                                   **MSC source**   **Assessment of MSC migration**                                                        **Therapeutic model and Administration method**                                                                                            **References**
  --------------------------------------------------------------- ---------------- -------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ ----------------
  Protocatechuic acid (PCA)                                       AMSC             Transwell method                                                                       --                                                                                                                                         [@B82]
  Cinnamtannin B-1                                                BMSC             Boyden chamber method, FACS analysis for MSC marker, Detection of luc-expressing MSC   Transdermal administration to the mouse model of skin wound healing                                                                        [@B11]
  Cannabinoids                                                    AMSC, BMSC       Boyden chamber method, Immunofluorescent analysis of MSC                               Implantation of the component-loaded microspheres in the rat model of bone-defect                                                          [@B70]; [@B26]
  Icariin (ICA)                                                   BMSC             Transwell method, Scratch wound method, Detection of BrdU-labeled MSC                  Preconditioning MSCs were injected intravenously into the rabbit model of cartilage-defect                                                 [@B23]; [@B97]
  Tanshinone IIA (Tan IIA)                                        BMSC             Transwell method, Detection of Dil-labeled MSC                                         Oral administration to the rat model of acute myocardial infarction                                                                        [@B75]
  Astragaloside IV (AS IV)                                        BMSC             Transwell method, Detection of Dio-labeled MSC                                         Preconditioning MSCs were injected intravenously into the rat model of acute myocardial infarction                                         [@B89]
  Tetramethylpyrazine (TMP)                                       BMSC             Transwell method, Detection of BrdU-labeled MSC                                        Preconditioning MSCs were injected intravenously into the rat model of cerebral ischemia, or Intraperitoneal administration to the model   [@B37], [@B38]
  Guanxin danshen formulation (GXDS) (Including Tanshinone IIA)   BMSC             Detection of GFP-expressing MSC                                                        Oral administration to the rat model of acute myocardial infarction                                                                        [@B16]

![A mechanistic overview of MSC recruitment to damaged sites by plant-derived components. Expression of CXCR4, a receptor for the chemokine CXCL12; activation of specific signaling molecules; expression and activation of MMPs, which are a part of the MSC migration machinery; and expression of CXCL12 (SDF-1) in damaged target tissues are stimulated by plant-derived components, leading to MSC migration.](fcell-08-00437-g001){#F1}

###### 

Plant-derived components stimulate signaling for MSC migration.

  **Component**                                                   **MSC source**   **Effects on MSC migration**                                       **References**
  --------------------------------------------------------------- ---------------- ------------------------------------------------------------------ ----------------
  Protocatechuic acid (PCA)                                       AMSC             Expression of MT1-MMP, and activation of MMP-2                     [@B82]
  Cinnamtannin B-1                                                BMSC             Activation of PI3K, PLC, lipoxygenase, and purines                 [@B11]
  Cannabinoids                                                    AMSC             Activation of Erk1/2 MAPK                                          [@B70]
  Icariin (ICA)                                                   BMSC             Activation of MAPKs (p38, Erk1/2, JNK), and Expression of CXCR4    [@B23]; [@B97]
  Tanshinone IIA (Tan IIA)                                        BMSC             Expression of CXCL12 (SDF-1) in target tissue, and CXCR4 in MSCs   [@B75]
  Astragaloside IV (AS IV)                                        BMSC             Expression of CXCR4                                                [@B89]
  Tetramethylpyrazine (TMP)                                       BMSC             Expression of CXCL12 (SDF-1) in target tissue, and CXCR4 in MSCs   [@B37], [@B38]
  Guanxin danshen formulation (GXDS) (Including Tanshinone IIA)   BMSC             Expression of CXCL12 (SDF-1) in target tissue                      [@B16]

Protocatechuic Acid {#S2.SS1}
-------------------

The phenolic compound protocatechuic acid (PCA) has been isolated from a number of herbs and edible plants ([@B29]). PCA has been reported to have various pharmacological effects such as anti-oxidant, anti-inflammatory, anti-hyperglycemic, anti-apoptotic and antimicrobial activity. PCA has also been shown to inhibit the proliferation and migration of airway smooth muscle cells in tracheal inflammatory conditions ([@B48]), while also suppressing the proliferation and migration of cardiac fibroblasts associated with p38 MAPK activation in a cardiac fibrosis model ([@B73]).

Additionally, studies on MSC migration, using Transwell assays and gelatin-coated membranes, have shown that PCA isolated from the kernel of Alpinia oxyphylla (0.5 mM or more) enhanced adipose tissue-derived mesenchymal stem cell (AMSC) migration ([@B82]), which subsequently inhibited initiation of early apoptotic events. Furthermore, following PCA treatment, cell morphology and surface markers remained unchanged, and AMSCs retained their osteocyte, adipocyte, and cardiomyocyte-like cell differentiation potential properties. Although PCA has been shown to stimulate AMSC proliferation, while retaining their functional pluripotency ([@B81]), it has also been reported that PCA has a stimulatory effect on osteocyte differentiation and a suppressive effect on adipocyte differentiation in mouse embryo-derived MSC ([@B65]).

The mechanism associated with PCA-stimulated MSC migration involves an increase in the expression of membrane-type matrix metalloproteinase-1 (MT1-MMP) and activation of matrix metalloproteinase-2 (MMP-2) in AMSCs. Since it has been reported that PCA activates three MAPKs (extracellular signal-regulated kinase1/2; Erk1/2, c-Jun N-terminal kinase; JNK and p38), which in turn activate the MMP signal in Schwann cell migration ([@B24]), PCA may serve to activate MAPKs involved in upstream signaling of MT1-MMP and MMP2 during AMSC migration. However, further studies are required to verify whether various doses of PCA activate MAPKs and promote migration of MSCs. MMPs play a key role in AMSC entry and migration through extracellular matrix (ECM) barriers, such as the basement membrane ([@B56]). In the process of cell migration across the ECM barrier, PCA-stimulated AMSCs may promote pericellular ECM degradation by MMPs, thereby partially promoting cell migration. These studies provide evidence for the mechanism by which PCA may facilitate MSC migration to organs in MSC therapy.

Cinnamtannin B-1 {#S2.SS2}
----------------

Cinnamtannin B-1 is a proanthocyanidin found in specific plants such as *Cinnamomum zeylanicum* ([@B68]). Cinnamtannin B-1 exhibits anti-inflammatory, anti-oxidant and anti-thrombotic properties ([@B50]), and also protects neurons from ischemia/reperfusion-induced dysfunction ([@B6]), while inhibiting survival of cancer cells ([@B3]), and protecting pancreatic acinar cells during pancreatitis ([@B64]).

*Mallotus philippinensis* bark extract also contains cinnamtannin B-1 ([@B12]). The use of this extract has been shown to increase migration of bone marrow-derived mesenchymal stem cells (BMSCs) and enhance wound healing in a mouse model ([@B12]). In fact, the efficacy of the extract on BMSC migration has been shown to be higher in comparison to other skin cell types. Histopathological features observed upon treatment with the extract indicated tissue repair by enhancement of angiogenesis and granulation tissue. *Mallotus philippinensis* fruit glandular hair also promoted wound healing via anti-oxidant and anti-inflammatory activity in a rat model ([@B13]).

Cinnamtannin B-1 has also been shown to promote BMSC migration when administered within the range of 0.8--2 μg/ml, and enhanced wound healing in a mouse model following topical administration (1.2 and 2.4 μg/wound) ([@B11]). Further, examination of BMSC recruitment in blood circulation via cell marker analysis showed that mobilization of endogenous MSCs into the blood increased following cinnamtannin B-1 treatment. Image analysis of an animal model implanted with luciferase-expressing BMSC indicated that cinnamtannin B-1 increased BMSC accumulation at the wound site and promoted wound healing. Furthermore, cinnamtannin B-1-induced BMSC migration was attenuated by inhibitors of PI3K, phospholipase C (PLC), lipoxygenase (LOX), and purine, implicating the associated signaling pathways in BMSC migration. In addition, morelloflavone, a biflavonoid constituent from *Garcinia vilersiana* Pierre with structural similarities to cinnamtannin B-1, also enhanced BMSC migration with a similar pharmacological profile ([@B27]). Therefore, structurally related compounds may also be effective in treating skin wounds by inducing mobilization of BMSCs.

Cannabinoid {#S2.SS3}
-----------

Cannabinoids are chemical components found in cannabis plants, with more than 100 varieties ([@B14]). The two primary types include cannabidiol (CBD) and tetrahydrocannabinol (THC), with the latter serving as the primary psychoactive component. CB1, CB2, TRPV1 and orphan G protein-coupled receptor GPR55, have been reported to exist as endogenous cannabinoid receptors ([@B18]). Cannabinoids have a variety of effects, in addition to their analgesic properties ([@B28]). Specifically, cannabinoids inhibit the growth and migration of gliomas ([@B77]), inhibit inflammation via neutrophil recruitment ([@B69]), promote wound healing through cell adhesion as well as migration of fibroblasts and keratinocytes ([@B83]; [@B42]), and promote bone formation by osteoblast regulation ([@B21]).

It has also been reported that CBD, administered within the range of 0.01--3 μM, increased AMSC migration in a dose-dependent manner ([@B70]). However, CBD-induced AMSC migration was antagonized by inhibition of the Erk1/2 MAPK pathway via attenuated Erk1/2 phosphorylation in the presence of a CB2 receptor antagonist and GRP55 agonist. Conversely, Erk1/2-dependent migratory effects were observed following stimulating with CB2 receptor agonist and GPR55 antagonist. Thus, the basis for CBD-induced MSC migration involves activation of CB2 or inhibition of GPR55, which subsequently activates Erk1/2. Furthermore, long-term treatment with CBD has been shown to differentiate AMSCs into osteoblasts ([@B70]). Hence, prolonged incubation of AMSC with CBD may enhance bone regeneration. In fact, recently, using a bone deficient rat model, it was reported that microspheres supplemented with CBD promoted the recruitment of MSCs and regeneration of bone defects ([@B26]).

Similarly, the major psychoactive component, Δ9-tetrahydrocannabinol (Δ9-THC), also increased AMSC migration ([@B51]). In the case of THC, migration of AMSCs is facilitated by CB1 through Erk1/2 activation, although THC has been reported to respond to both CB1 and CB2 ([@B58]). However, since cannabinoids can respond to many functional proteins, further research is needed to obtain a complete understanding of their pharmacological effects ([@B18]).

Icariin {#S2.SS4}
-------

Icariin (ICA) is a flavonoid glycoside isolated from *Epimedium* and is a primary component of the Chinese herb Herba Epimedii ([@B35]). It has been reported that ICA possesses broad therapeutic activities, such as anti-oxidant, tonic, aphrodisiac, neuro-protective, cardio-protective, anti-rheumatic, anti-cancer, and anti-osteoporotic effects ([@B35]). ICA has also been reported to promote BMSC proliferation, bone formation, and chondrogenic differentiation ([@B86]; [@B62]). Furthermore, treatment of AMSCs with ICA in a rat model of diabetes-related erectile dysfunction, protected against oxidative stress via PI3K signaling and improved AMSC survival, leading to enhanced therapeutic potential ([@B84]). Furthermore, combining ICA and MSCs was shown to promote angiogenesis and neurogenesis, as a result of increased production of VEGF and brain-derived neurotrophic factor (BDNF) through activation of PI3K and Erk1/2 MAPK, in an ischemic stroke rat model ([@B43]). ICA may also improve wound and periodontal pathology by promoting keratinocyte proliferation and migration, as well as by promoting survival and migration of periodontal ligament fibroblasts ([@B44]; [@B54]).

ICA administered at 1 μM was reported to significantly increase BMSC migration by stimulating actin stress fiber formation ([@B23]). MAPK signals, such as p38, Erk1/2 and JNK, were activated during BMSC migration following ICA stimulation. In the presence of MAPK inhibitors, BMSC migration was also inhibited, and actin stress fiber formation was abolished. Thus, ICA may promote BMSC migration by increasing actin stress fiber formation through MAPK signaling. ICA also promotes CXCR4 expression, which is a signaling molecule upstream of MAPK, in BMSC migration through the activation of hypoxia inducible factor-1 (HIF-1) ([@B97]). Moreover, transplantation of ICA-treated BMSCs in a cartilage-deficient rabbit model, accelerated the migration of BMSCs to the cartilage-deficient region in comparison to non-treated BMSCs ([@B23]). These results suggest that ICA-treated BMSC may be effective in treating cartilage defects.

Tanshinone IIA {#S2.SS5}
--------------

Tanshinone IIA (Tan IIA) is a diterpene quinone and one of the major active compounds of *Salvia miltiorrhiza* (Lamiaceae) ([@B63]). *Salvia miltiorrhiza* has been widely used as a herbal medicine in the clinical treatment of cardiovascular diseases ([@B40]). Tan IIA has anti-oxidant and anti-inflammatory properties as well as multiple pharmacological benefits such as cardio-protection, neuroprotection, vascular protection, and anti-cancer effects ([@B40]; [@B63]). As for cell migration, Tan IIA has been shown to inhibit vascular endothelial cell proliferation and migration by inhibiting VEGF expression and its signaling pathways ([@B90]; [@B10]; [@B34]).

Tan IIA has been reported to have an effect on MSC differentiation including promoting osteogenic differentiation in BMSCs ([@B61]), cord blood MSCs ([@B17]), Wharton's jelly MSCs ([@B2]), and periodontal ligament stem cells ([@B47]). In addition, Tan IIA effectively induced the differentiation of cord blood MSCs into liver cells in a rat model of cirrhosis ([@B92]), BMSCs into neuronal cells in a rat spinal cord injury model ([@B95]), and placental MSCs into cardiomyocytes *in vitro* ([@B36]). Furthermore, it has been reported that Tan IIA combined with MSC treatment exhibited a neuronal protective effect via suppression of neuronal apoptosis in a vascular dementia rat model ([@B31]), as well as by suppressing amyloid-related protein production and inflammation in an Aβ25-35-induced AD rat model ([@B20]).

Additionally, administration of 1--4 μM Tan IIA has been shown to significantly enhance BMSC migration ([@B75]). In a rat model of acute myocardial infarction, oral administration of Tan IIA at 30 mg/kg/d combined with BMSC transplantation increased BMSC recruitment to the damaged area following myocardial infarction, resulting in restored normal function of the left ventricle (LV) systolic and end-diastolic pressure, as well as enhanced VEGF expression in the infarcted region. Immunological detection of the occlusion site also suggests that Tan IIA may promote CXCL12 expression in the infarcted area, while increasing CXCL12 levels in peripheral blood. However, Tan IIA-induced BMSC migration was inhibited by a CXCR4 blocker. Furthermore, Tan IIA treatment was shown to enhance CXCR4 expression in BMSCs. These results suggest that Tan IIA increases CXCL12 expression at the site of injury, and increases BMSC migration by enhancing CXCR4 expression in BMSCs. Thus, Tan IIA may be effective in treating ischemic heart disease by MSC therapy.

Astragaloside IV {#S2.SS6}
----------------

Astragaloside IV (AS IV) is an active saponin and the major active ingredient of Astragalus membranaceus, used in traditional Chinese medicine ([@B39]). Astragalus membranaceus, commonly used with *S. miltiorrhiza* including Tan IIA, is commonly used to enhance cardiovascular disease protection ([@B79]). Moreover, AS IV has demonstrated pharmacological action for cerebral injury, cardiovascular disease, liver, diabetic nephropathy, and cancer ([@B39]). It has also been shown to reduce infarct size and arrhythmias, while improving ventricular function in ischemic heart disease ([@B91]). In cell migration, AS IV treatment enhances the proliferation and migration of a human osteoblast-like cell line, which may be facilitated by activation of the Hedgehog signaling pathway ([@B15]). AS IV also inhibits proliferation and migration of human dermal vascular smooth muscle cells, stimulated by PDGF-BB secreted during vascular injury, through inhibition of p38 MAPK signaling ([@B5]). It has also been reported that AS IV and Tan IIA promote tubular structure formation of BMSC-derived endothelial cell cells, similar to that of blood vessels, via the expression of connexins and cell connection ([@B41]).

Lastly, BMSCs stimulated with AS IV, administered at 0.4 μg/ml, was reported to increase CXCR4 expression, indicating that BMSC migration to its ligand CXCL12 was enhanced ([@B89]). In addition, this enhanced migration was suppressed by CXCR4 inhibitors. Additionally, in a rat model of acute myocardial infarction, BMSCs stimulated with AS IV displayed increased homing to ischemic myocardial sites, suggesting that AS IV enhances BMSC recruitment via increased CXCR4 expression. Although the effect of AS IV on MSC migration was not as strong as that observed with Tan IIA, when the two components are administered together, a synergistic enhancement of BMSC migration was observed, hence this combinatorial strategy may increase the efficacy of MSC transplant therapy.

Tetramethylpyrazine {#S2.SS7}
-------------------

Tetramethylpyrazine (TMP) is pyrazine and an alkaloid isolated from Rhizoma Chuanxiong (*Ligusticum wallichii*) ([@B96]). TMP functions as a neuro-protective, anti-apoptotic, anti-cancer, vasodilator, and anti-inflammatory agent ([@B96]). With respect to cell migration, TMP increases brain microvascular endothelial cell proliferation and migration by partially increasing VEGF secretion ([@B94]), and promoting migration of the neural progenitor by inducing CXCL12 expression through activation of the PI3K pathway ([@B32]). Alternatively, TMP inhibits the migration of neutrophils activated by inflammation in a rat cerebral ischemia model, which was reported to involve Akt and Erk signaling ([@B4]).

TMP was also shown to enhance growth and neuronal differentiation of BMSCs. Further, it was suggested to have anti-aging effects on the nervous system ([@B74]). A Chinese therapy, the Jiuxin pill, containing TMP and borneol, is known to promote exosome secretion from cardiac MSCs, which may have a positive therapeutic effect on heart disease ([@B67]). In MSC migration, pretreatment with 10--200 μM TMP, causes increased BMSC migration in a dose-dependent manner ([@B37]). TMP also promoted CXCR4 expression, which was inhibited by a CXCR4 blocker. Intravenous administration of TMP-pretreated BMSCs into a cerebral ischemic rat model demonstrated improved neurological function and enhanced recruitment of BMSCs to cerebral ischemic sites. In addition, angiogenesis and the expression of both CXCL12 and CXCR4 were promoted at the ischemia site. In a separate study, the combination of transplanted BMSCs and intraperitoneal administration of TMP (40 mg/kg/d) in a cerebral ischemia model not only promoted the CXCL12/CXCR4 axis, but also regenerated blood vessels and nerves via enhancement of VEGF and BDNF expression, leading to functional recovery ([@B38]). Taken together, these results show that the combination of MSCs and TMP may contribute to CXCL12/CXCR4 axis augmentation and neuronal regeneration, suggesting that they may be effective in treating cerebral ischemic injury.

Guanxin Danshen Formulation {#S2.SS8}
---------------------------

Guanxin Danshen (GXDS), a Chinese herbal medicine, is an effective formulation for the treatment of ischemic heart diseases ([@B8]). The GXDS formulation is comprised of three materials: *Salvia miltiorrhiza* (Lamiaceae), *Panax notoginseng* (Lamiaceae), and *Dalbergia odorifera* (Fabaceae). It contains Tanshinone IIA, salvianolic acid B ([@B85]), ginsenoside Rb1, ginsenoside RG1, notoginsenoside R1 ([@B78]), and flavanols ([@B45]).

GXDS has also proven effective in MSC treatments. For instance, oral administration of GXDS (100 mg/kg/d) in combination with BMSC transplantation in a rat model of acute myocardial infarction improved cardiac function of the LV ejection fraction, LV fractional shortening, and LV end-systolic volume ([@B16]). In addition, GXDS administration in combination with BMSC transplantation not only reduced cell apoptosis detected by TUNEL staining, but also enhanced peri- and infarcted angiogenesis, increased local CXCL12 expression and the number of BMSCs homing to the infarcted area, while also reducing the size of the myocardial infarction region. Therefore, it is suggested that GXDS increases the migration of MSCs by up-regulating the expression of CXCL12 at the site of infarction. However, since this formulation may contain Tan IIA, it is possible that this component could have contributed to the observed effects ([@B75]). Nevertheless, the combination of GXDS and MSC therapy has the potential to improve ischemic heart disease, including myocardial infarction.

Moreover, other Chinese herbal extracts have been shown to stimulated MSC migration. For example, oily extract from *Catharmus tinctorius* (1--50 μg/ml) promotes rat BMSC migration through Rho-associated protein kinase 2 (ROCK2) signaling *in vitro* ([@B47]). In addition, Bushen Huoxue decoction (100 μg/ml), a mixture comprised of eleven Chinese herbs, increase rat BMSC migration *in vitro* by regulating MiR-539-5p miRNA ([@B19]) and activating Wnt5a-related cell motility ([@B72]). Despite these observations, none of the individual compounds responsible have been identified from these extracts.

Discussion {#S3}
==========

This article focused on a comprehensive review of plant-derived components that increase MSC migration and promote recovery from tissue damage. Studies on the promotion of MSC migration by plant-derived components have exposed a variety of characteristics and advantages ([Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). For example, although PCA was only found to be effective at high doses, its potential has been demonstrated and has been suggested to function by increasing the expression and activation of MMPs, which then degrade the ECM to enhance MSC invasion into tissues ([@B82]). Studies on cinnamtannin B-1 have shown that structurally related flavonoids also have MSC migration activity ([@B11]). Thus, expanding upon this structural framework offers the potential to develop more active compounds through structure-based drug development. Since CBD, a non-psychoactive cannabinoid, can promote MSC migration and bone differentiation, and is currently being therapeutically developed, for example in sustained-release drugs from the encapsulated microspheres of biodegradable polymers, it represents a potentially advanced option for bone repair ([@B70]; [@B26]). ICA, when used to pretreat MSCs, promote their migration to cartilage-defect sites ([@B23]; [@B97]), as well as their proliferation ([@B62]), bone differentiation ([@B35]), and cartilage differentiation ([@B86]), and thus, may significantly improve healing related to skeletal defects. Tan IIA has been shown to increase CXCL12 expression at the site of injury as well as CXCR4 on transplanted MSCs, leading to enhanced MSC migration to the injured area, which may prove effective in the treatment of ischemic heart disease ([@B75]). Interestingly, AS IV and Tan IIA were found to synergistically enhance MSC migration, thus presenting potential for combined therapeutic approaches involving plant-derived components ([@B89]). The use of TMP in combination with MSCs, or as a pretreatment agent, not only promotes the migration of MSCs to the site of injury, but also enhances the effect of MSCs on the regeneration of nerves and blood vessels ([@B37], [@B38]). Consequently, TMP has potential for the treatment of cerebral ischemia damage. Finally, GXDS, when administered orally, in combination with MSC transplantation, may improve acute myocardial infarction by reducing apoptosis at the site of injury, generating new blood vessels, and promoting MSC migration by increasing CXCL12 expression ([@B16]).

The diverse array of mechanisms by which plant-derived components facilitate MSC migration include ECM remodeling, activation of intracellular signaling pathways, such as PI3K and MAPK, and enhanced expression of the CXCL12/CXCR4 axis ([Figure 1](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). The plants from which these compounds have been isolated have been used in traditional medicine practices and as such, a significant amount of useful information is available with regard to their use in several indications. Many associated factors have already been analyzed in detail, including their identification, structural classification and therapeutic efficacy. Since each plant-derived component exhibits therapeutic effects in specific conditions, the disease models are designed based on the indication of the components, expecting the synergistic effects in MSC therapy ([Table 3](#T3){ref-type="table"}). Consequently, these disease models have demonstrated the benefits of MSC treatment as well as the additional therapeutic effects of many plant-derived components. Furthermore, medicinal plants have many uses and often have the advantage of being administered orally. The methods of administering plant-derived components *in vivo* for MSC migration enhancement include MSC pretreatment, as well as transdermal, intravenous, intraperitoneal and oral approaches.

###### 

Therapeutic effects of plant-derived components and their effects on MSCs.

  **Component**                                                   **Plant**                                                                                              **Therapeutic effects of component**                                                                                                                                                                                                                                                                                                                                                                     **Effects of component on MSC**                                                                                                                                                                                                                  **Therapeutic model by component and MSC transplantation**
  --------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------
  Protocatechuic acid (PCA)                                       Alpinia oxyphylla (Zingiberaceae) [@B29]                                                               Anti-oxidant, Anti-inflammatory, Anti-hyperglycemic, Anti-apoptotic, Antimicrobial [@B29], Inhibition of the proliferation and migration of airway smooth muscle cells in tracheal inflammatory conditions [@B48], Suppression of the proliferation and migration of cardiac fibroblasts in a cardiac fibrosis [@B73], Activation of the MMP signal in Schwann cell migration [@B24]                     Migration [@B82], Proliferation [@B81], Stimulatory on osteocyte differentiation and suppressive on adipocyte differentiation [@B65]                                                                                                             --
  Cinnamtannin B-1                                                Mallotus philippinensis (Euphorbiaceae) [@B12]                                                         Anti-oxidant, Anti-inflammatory, Anti-thrombotic [@B50], Neuro-protective [@B6], Pancreatic-protective [@B64], Anti-cancer [@B3], Wound healing [@B13]                                                                                                                                                                                                                                                   Migration [@B12]; [@B11]                                                                                                                                                                                                                         Wound healing [@B11]
  Cannabinoids                                                    Cannabis sativa (Cannabaceae) [@B14]                                                                   Analgesic effects [@B28], Anti-inflamatory [@B69], Anti-gliomas [@B77], Wound healing [@B83]; [@B42], Bone formation [@B21]                                                                                                                                                                                                                                                                              Migration [@B70]; [@B51], Osteocyte differentiation [@B70]                                                                                                                                                                                       Bone-defect [@B26]
  Icariin (ICA)                                                   Epimedium (Berberidaceae) [@B35]                                                                       Anti-oxidant, Tonic, Aphrodisiac, Neuro-protective, Cardio-protective, Anti-rheumatic, Anti-cancer, Anti-osteoporotic [@B35], Wound healing by effects for keratinocyte proliferation and migration [@B54], Improvement of periodontal pathology by effects for survival and migration of periodontal ligament fibroblasts [@B44]                                                                        Migration [@B23]; [@B97], Proliferation, Osteocyte differentiation [@B62], Chondrogenic differentiation [@B86], Cell survival [@B84], Neuronal regeneration in cooperation with MSCs [@B43]                                                      Cartilage-defect [@B23], Diabetes-associated erectile dysfunction [@B84], Cerebral ischemia [@B43]
  Tanshinone IIA (Tan IIA)                                        Salvia miltiorrhiza (Lamiaceae) [@B63]                                                                 Anti-oxidant, Anti-inflammatory, Cardio-protective, Neuro-protective, Vascular- protective, Anti-cancer [@B40]; [@B63] Inhibition of vascular endothelial cell proliferation and migration in angiogenesis-related pathologies [@B90]; [@B10]; [@B34]                                                                                                                                                    Migration [@B75], Osteogenic differentiation [@B61]; [@B17]; [@B2]; [@B47], Hepatocyte differentiation [@B92], Neuronal differentiation [@B95], Cardiomyocyte differentiation [@B36], Neuro-protection in cooperation with MSCs [@B31]; [@B20]   Acute myocardial infarction [@B75] Liver cirrhosis [@B92], Spinal cord injury [@B95], Vascular dementia [@B31], Aβ25-35-induced AD [@B20]
  Astragaloside IV (AS IV)                                        Astragalus membranaceus (Leguminosae) [@B39]                                                           Anti-oxidant, Anti-inflammatory, Cardio-protective, Neuro-protective, Hepato-protective, Nephro-protective, Anti-cancer [@B39], Improvement of ventricular function in ischemic heart disease [@B91], Enhancement of the proliferation and migration of a human osteoblast-like cell [@B15], Inhibition of the abnormal proliferation and migration of human dermal vascular smooth muscle cells [@B5]   Migration [@B89], Angiogenesis of MSC-derived endothelial cell-like cells by co-stimulation with Tan IIA [@B41]                                                                                                                                  Acute myocardial infarction [@B89]
  Tetramethylpyrazine (TMP)                                       Rhizoma Chuanxiong (Ligusticum wallichii) [@B96]                                                       Anti-oxidant, Anti-inflammatory, Neuro-protective, Anti-apoptotic, Anti-cancer, Vasodilator [@B96], Increase of brain microvascular endothelial cell proliferation and migration [@B94], Promotion of migration of the neural progenitor [@B32], Inhibition of the migration of neutrophils activated by inflammation [@B4].                                                                             Migration [@B37], [@B38], Neuronal differentiation [@B74], Jiuxin pill containing TMP promotes exosome secretion from MSCs [@B67] Angiogenesis in cooperation with MSCs [@B37], [@B38] Neurogenesis in cooperation with MSCs [@B38]              Cerebral ischemia [@B37], [@B38]
  Guanxin danshen formulation (GXDS) (Including Tanshinone IIA)   Salvia miltiorrhiza (Lamiaceae), Panax notoginseng (Lamiaceae), Dalbergia odorifera (Fabaceae) [@B8]   Cardio-protective [@B8]                                                                                                                                                                                                                                                                                                                                                                                  Migration [@B16]                                                                                                                                                                                                                                 Acute myocardial infarction [@B16]

Mesenchymal stem cells are believed to play an important role in tissue regeneration after organ damage, and MSC-based therapeutic approaches have been implemented in a variety of disease models ([@B59]). Methods to control the kinetics of transplanted MSCs can be very useful in a variety of applications, including organ regeneration, protection from tissue damage, and treatment of refractory cancers ([@B57]; [@B1]). Herein, we have provided a comprehensive review of plant-derived components that control the migration of MSCs, and may offer novel therapeutic options for regenerative medicine.

Challenges and Future Prospects {#S3.SS1}
-------------------------------

Currently, a gap exists between cell-level migration and *in vivo* recruitment. Additionally, several issues have been described including, how to achieve specificity and effective dosing for MSC *in vivo*, how to confirm component toxicity, and how to address the limitations of MSC dynamic tracking technology *in vivo* for cell kinetic analysis of MSC transplant ([@B33]). To solve these issues, tests for drug development must determine the tissue specificity and effective dose of each component *in vivo*, as well as analyze individual toxicity.

As a supplement to cell dynamic analysis, it is also necessary to accumulate omics information on the effects of plant-derived components on MSC mobilization in disease models. For example, with the progress of MSC research, analysis of single cells using techniques such as RNA-Seq, will allow for examination of detailed cellular functions along with the MSC fates at the genetic level ([@B46]). Moreover, the effects and suitability of plant-derived components in various MSCs at the genetic level may be elucidated. Furthermore, it has been shown that exosomes secreted by MSCs have a healing effect, and contain a large number of biomolecules such as miRNAs, cytokines, growth factors and enzymes, thereby demonstrating that advances are being made in defining the molecular basis for the therapeutic action of MSCs ([@B93]).

Conclusion {#S4}
==========

Plant-derived components, which promote MSC migration, accelerate the healing of tissue damage. Moreover, MSC migration by plant-derived components may be mediated by signaling molecules such as CXCL12/CXCR4, PI3K, MAPK, and MMPs. Ingredients derived from medicinal plants are useful as there already exists invaluable information on medicinal plants for traditional use. In addition, the structural characteristics of plant-derived components are important to understand their effect on MSC migration activity, and may be potential seeds for drug discovery. Therefore, plant-derived components that enhance MSC recruitment to damaged sites may provide novel tools for improved treatment approaches.
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